Drug Profile
CC 90002
Alternative Names: Anti-CD47 Antibody - Celgene; Ca ImmRx; CC-90002; INBRX-103Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Inhibrx
- Developer Celgene Corporation
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
- No development reported Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain (IV, Infusion)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (IV, Infusion)